{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:37:56Z","timestamp":1775151476498,"version":"3.50.1"},"reference-count":27,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2005,5,5]],"date-time":"2005-05-05T00:00:00Z","timestamp":1115251200000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2005,5]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To characterize osteoprotegerin (OPG) levels, bone remodelling and bone mineral density (BMD) in heavily pretreated HIV\u2010infected patients on antiretroviral therapy, and to evaluate the clinical factors associated with bone density decline.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Heavily pretreated (&gt;5 years) HIV\u2010positive patients were enrolled in this cross\u2010sectional, observational study, which was based on a total body bone densitometry examination and a comprehensive evaluation of bone and mineral parameters.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sixty\u2010eight patients (55 male and 13 female) with a median age of 41 years (range 25\u201360 years) were included in the study. Their antiretroviral treatment lasted for 82 months. On the basis of the World Health Organization criteria, nine patients (13.2%) were osteoporotic [T\u2010score&lt;\u22122.5 standard deviation (SD)] and 19 patients (27.9%) were osteopenic (T\u2010score between\u22121 and\u22122.5). The principal outcomes associated with the presence of a low BMD were high OPG and lysylpyridinoline\/creatinine ratio (Dpd) values. Most of the patients (39 of 48; 81.25%) showed vitamin D insufficiency [Vitamin D (25(OH)D)&lt;18 ng\/mL] with secondary hyperparathyroidism (13 of 50 patients: 26%), which proved to be correlated to osteocalcin (BGP) levels [parathyroid hormone (PTH) vs. BGP: <jats:italic>r<\/jats:italic>=0.34; <jats:italic>P<\/jats:italic>&lt;0.01]. There was an inverse correlation between T\u2010scores and serum osteocalcin and alkaline phosphatase (AP) levels, on one hand, and Dpd, on the other. High AP and Dpd values were associated with relative risks of 4.1 [95% confidence interval (CI)=1.01\u201317.6] and 7.2 (95% CI=1.67\u201331.03), respectively, of a pathological T\u2010score. Multivariate analysis revealed that the factors associated with the presence of osteopenia or osteoporosis were older age and lower body mass index.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>About 40% of our heavily pretreated subjects with advanced HIV infection had a low BMD, and 56% (24 of 44 patients) showed a high bone turnover rate with marked osteoclast activation. High OPG levels may protect against bone resorption.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2005.00278.x","type":"journal-article","created":{"date-parts":[[2005,5,5]],"date-time":"2005-05-05T13:50:23Z","timestamp":1115301023000},"page":"145-150","source":"Crossref","is-referenced-by-count":44,"title":["Osteoprotegerin and bone turnover markers in heavily pretreated HIV\u2010infected patients"],"prefix":"10.1111","volume":"6","author":[{"given":"E","family":"Seminari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Soldarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Galli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Fusetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Dorigatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Hasson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Danise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Guffanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Lazzarin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Rubinacci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,5,5]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"257","article-title":"Management of metabolic complications associated with antiretroviral therapy for HIV\u20101 infection","volume":"31","author":"Schambelan M","year":"2002","journal-title":"recommendations of an International AIDS Society-USA panel"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01728893"},{"key":"e_1_2_5_4_2","first-page":"145","article-title":"Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection","volume":"84","author":"Aukrust P","year":"1999","journal-title":"indication of normalization of the bone-remodeling process during highly active antiretroviral therapy"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200101260-00022"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/8756-3282(94)00028-X"},{"key":"e_1_2_5_7_2","first-page":"703","article-title":"Osteopenia in HIV\u2010infected men","volume":"15","author":"Carr A","year":"2001","journal-title":"association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy"},{"key":"e_1_2_5_8_2","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/ajcn\/74.5.679","article-title":"Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV\u2010seropositive men and women","volume":"74","author":"McDermott AY","year":"2001","journal-title":"Am J Clin Nutr"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200003100-00005"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200105250-00005"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1450685"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200109280-00011"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/367569"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/375884"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1258\/136218003100322080"},{"key":"e_1_2_5_16_2","first-page":"5050","article-title":"Minireview","volume":"142","author":"Khosla S.","year":"2001","journal-title":"the OPG\/RANKL\/RANK system"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(88)90274-6"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.5.2020"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200307040-00027"},{"key":"e_1_2_5_20_2","first-page":"2239","article-title":"Osteoblasts in HIV\u2010infected patients","volume":"15","author":"Nacher M","year":"2001","journal-title":"HIV-1 infection and cell function"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/325062a0"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200303070-00006"},{"key":"e_1_2_5_23_2","unstructured":"TebasP YarasheskiKE WhyteMet al.Serum and urine markers of bone mineral metabolism in HIV infected patients taking protease inhibitor containing potent antiretroviral therapy.Second International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Toronto Canada September 2000 [Abstract 029]."},{"key":"e_1_2_5_24_2","first-page":"405","article-title":"Bone mass in HIV\u2010infected patients","volume":"33","author":"Vescini F","year":"2003","journal-title":"focus on the role of therapy and sex"},{"key":"e_1_2_5_25_2","first-page":"518","article-title":"Immunological characterization of circulating osteoprotegerin\/osteoclastogenesis inhibitory factor","volume":"14","author":"Yano K","year":"1999","journal-title":"increased serum concentrations in postmenopausal women with osteoporosis"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81569-X"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C200069200"},{"key":"e_1_2_5_28_2","first-page":"171","article-title":"The fallacy of BMD","volume":"19","author":"Nielesen SP.","year":"2000","journal-title":"a critical review of the diagnostic use of dual X-ray absorptiometry"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2005.00278.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2005.00278.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T15:17:05Z","timestamp":1696951025000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2005.00278.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["10.1111\/j.1468-1293.2005.00278.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2005.00278.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}